Table 4.

RR of ovarian cancer by quartiles of anti-MUC1 antibodies in the Nurses' Health Studies

Quartiles of anti-MUC1 antibodies*
Q1Q2Q3Q4P-trendQ1 vs Q2,3,4
All women
    Cases, N (%)36 (31)28 (24)27 (23)26 (22)81 (69)
    Controls, N (%)84 (25)86 (25)84 (25)85 (25)255 (75)
RR (95% CI)1.000.73 (0.40-1.34)0.74 (0.41-1.35)0.72 (0.39-1.31)0.300.73 (0.45-1.18)
Age <64 y§
    Cases, N (%)29 (32)23 (26)20 (22)18 (20)61 (68)
    Controls, N (%)52 (20)68 (26)63 (25)74 (29)205 (80)
    RR (95% CI)1.000.60 (0.30-1.19)0.58 (0.29-1.15)0.45 (0.23-0.91)0.030.53 (0.31- 0.93)
Age ≥64 y§
    Cases, N (%)7 (26)5 (19)7 (26)8 (30)20 (74)
    Controls, N (%)32 (39)18 (22)21 (26)11 (13)50 (61)
    RR (95% CI)1.001.36 (0.35-5.23)1.83 (0.50-6.73)3.95 (1.05-14.9)0.052.11 (0.73-6.04)

NOTE: Absorbance readings at 1:40.

  • *Median anti-MUC1 antibody levels in quartiles 1, 2, 3, and 4 were 0.29, 0.47, 0.68, and 1.16, respectively (among all women regardless of age).

  • Wald statistic P-values modeling antibody quartiles weighted by their median antibody values linearly.

  • Conditional logistic regression stratified on matching factors (age, menopause status, date of and fasting status at blood collection, and menopause status at time of cases' diagnosis).

  • §The likelihood ratio test P-value for interaction between antibodies (weighted quartiles modeled linearly) and age (in years) was 0.005.